The Coronary Plaque Reimbursement Playbook: Inside Elucid's $55M Raise and the Economics of Non-Invasive Cardiovascular AI
Dr. Dereck Mush, MD, MBA
Elucid
Utilizes AI driven CT angiography analysis to quantify arterial plaque and patient risk.
What they do
Provides non invasive imaging software that uses AI to analyze CT angiography scans, performing virtual histology to quantify plaque composition and assess stability. Cardiologists use the tool to predict ischemic events and customize patient treatment plans.
The record
- Vertical
- Cardiovascular
- Sub-segment
- Cardiovascular imaging AI
- Product type
- Software as a medical device
- Stage
- Series C+
- Headquarters
- Boston, United States
- Region
- North America
- Founded
- 2013
- Total funding
- $121M raised
Notable investors: Elevage Medical Technologies, Industry Ventures, Bold Brain Ventures, Medtech Convergence Fund.
Also in Cardiovascular
Related on The Signal
Dr. Dereck Mush, MD, MBA
Top 25 Cardiologists to Follow on LinkedIn in 2026
Dr. Dereck Mush, MD, MBA
Menopause benefits are expanding past hot flashes into cardiovascular and bone health
Dr. Dereck Mush, MD, MBA
The ECG-to-Echo Pathway: Where Tempus ECG-MR Must Prove Its Value
Dr. Dereck Mush, MD, MBA